PE20090675A1 - Composicion farmaceutica que contie levosimendan y un antagonista receptor de angiotensina ii o un inhibidor eca - Google Patents

Composicion farmaceutica que contie levosimendan y un antagonista receptor de angiotensina ii o un inhibidor eca

Info

Publication number
PE20090675A1
PE20090675A1 PE2008001464A PE2008001464A PE20090675A1 PE 20090675 A1 PE20090675 A1 PE 20090675A1 PE 2008001464 A PE2008001464 A PE 2008001464A PE 2008001464 A PE2008001464 A PE 2008001464A PE 20090675 A1 PE20090675 A1 PE 20090675A1
Authority
PE
Peru
Prior art keywords
angiotensin
pharmaceutical composition
receptor antagonist
composition containing
ace inhibitor
Prior art date
Application number
PE2008001464A
Other languages
English (en)
Inventor
Jukka Sallinen
Mikko Kuoppamaki
Jouko Levijoki
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40043957&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090675(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corp filed Critical Orion Corp
Publication of PE20090675A1 publication Critical patent/PE20090675A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE COMO PRIMER INGREDIENTE ACTIVO LEVOSIMENDAN O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO Y COMO SEGUNDO INGREDIENTE ACTIVO UN ANTAGONISTA RECEPTOR DE ANGIOTENSINA II SELECCIONADA DE LOSARTAN, VALSARTAN, TELMISARTAN, EPROSARTAN, CANDESARTAN, ENTRE OTROS O UN INHIBIDOR DE ENZIMA CONVERSIVA DE LA ANGIOTENSINA SELECCIONADO DE RAMIPRIL, CAPTOPRIL, ENALAPRIL, QUINAPRIL, ENTRE OTROS. DICHA COMPOSICION TIENE UN EFECTO SINERGICO EN LA REDUCCION DE COMPLICACIONES HIPERTENSIVAS Y MORTALIDAD ASOCIADAS CON APOPLEJIA
PE2008001464A 2007-08-29 2008-08-29 Composicion farmaceutica que contie levosimendan y un antagonista receptor de angiotensina ii o un inhibidor eca PE20090675A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96858307P 2007-08-29 2007-08-29

Publications (1)

Publication Number Publication Date
PE20090675A1 true PE20090675A1 (es) 2009-06-13

Family

ID=40043957

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001464A PE20090675A1 (es) 2007-08-29 2008-08-29 Composicion farmaceutica que contie levosimendan y un antagonista receptor de angiotensina ii o un inhibidor eca

Country Status (8)

Country Link
US (1) US20100249103A1 (es)
EP (1) EP2185141A1 (es)
AR (1) AR068814A1 (es)
CA (1) CA2695822A1 (es)
CL (1) CL2008002555A1 (es)
PE (1) PE20090675A1 (es)
TW (1) TW200920371A (es)
WO (1) WO2009027577A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011027021A1 (en) 2009-09-01 2011-03-10 Orion Corporation A method for the treatment of hypertension
CN106214680B (zh) * 2016-07-29 2018-05-11 珠海赛隆药业股份有限公司（长沙）医药研发中心 一种血管紧张素受体拮抗剂和左西孟旦的复合物及其用途
AU2020408323A1 (en) 2019-12-16 2022-08-11 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HF-pEF)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0003982A3 (en) * 1997-10-17 2002-01-28 Eurogene Ltd The use of inhibitors of the renin-angiotensin system for producing pharmaceutical compositions using for the treatment of hypoxia or impaired metabolic function
US5905078A (en) 1998-06-19 1999-05-18 Orion Corporation Use of a pyridazinone derivative
TWI299663B (en) * 2002-05-14 2008-08-11 Novartis Ag Methods of treatment
FI20040674A0 (fi) 2004-05-12 2004-05-12 Orion Corp Menetelmä tromboembolisten sairauksien estoon
EP1908469A1 (en) * 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats

Also Published As

Publication number Publication date
CA2695822A1 (en) 2009-03-05
US20100249103A1 (en) 2010-09-30
TW200920371A (en) 2009-05-16
EP2185141A1 (en) 2010-05-19
AR068814A1 (es) 2009-12-09
WO2009027577A1 (en) 2009-03-05
CL2008002555A1 (es) 2009-04-03

Similar Documents

Publication Publication Date Title
PE20110927A1 (es) Forma de dosificacion farmaceutica que comprende nifedipino o nisolpino y un antagonista de angiotensina ii
PE20140978A1 (es) Composicion farmaceutica solida que contiene amlodipina y losartan y el proceso para producirla
JP2018507244A5 (es)
GT201400012A (es) Compuesto inhibidor de la señalizacion de la trayectoria notch
GT200900328A (es) Derivados de bencimidazol
BR112012024019A2 (pt) forma de dosagem de liberação controlada, e, método para liberar uma droga
AR051618A1 (es) Comprimido bicapa y metodo
CY1110097T1 (el) Διπλοστοιβαδικο δισκιο για προληψη καρδιαγγειακων συμβαντων
GB2454620A (en) Solid dosage form of olmesartan medoxomil and amlodipine
GT200900284A (es) Dosis intravenosa y oral de un inhibidor p2y12 de accion directa y reversible.-
EA201690679A1 (ru) Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан
PE20121131A1 (es) Composicion farmaceutica oral solida en comprimido monocapa que comprende irbesartan y besilato de amlodipina
PE20141049A1 (es) Composicion farmaceutica antihipertensiva
EA201171497A1 (ru) Снижение флуктуаций опиоидов в крови
UA111599C2 (uk) Композиція каспофунгіну
RU2015110979A (ru) Комбинации ингибиторов sglt 2 и антигипертензивных лекарственных средств
AR111471A2 (es) Composición de combinación sinérgica
PE20090675A1 (es) Composicion farmaceutica que contie levosimendan y un antagonista receptor de angiotensina ii o un inhibidor eca
EA201390979A1 (ru) Композиции бензимидазолов с модифицированным высвобождением
EA201390603A1 (ru) Многослойная фармацевтическая композиция, содержащая телмисартан и амлодипин
IT1401284B1 (it) Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system).
AR096350A1 (es) Composición farmacéutica para administración por vía oral para su uso para la prevención y/o el tratamiento de una enfermedad cardiovascular
RU2016126852A (ru) Комбинированный фармацевтический препарат, содержащий блокатор рецептора ангиотензина-II и ингибитор ГМГ-КоА редуктазы
TR201803451T4 (tr) Olmesartan formülasyonlari.
CL2011002444A1 (es) Composicion farmaceutica que contiene un liposoma y el compuesto activo eribulina o su sal farmacologicamente permisible en la fase interna del liposoma; y el metodo de manufactura de la composicion de liposoma.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed